Toxocara-induced eosinophilic inflammation. Airway function and effect of anti-IL-5.
The immunoinflammatory response to parasitic nematode infections and allergic diseases have some similarities, the most profound being the increases in eosinophils and serum total IgE concentration. Whether parasitic infections stimulate or inhibit allergic asthma is a matter of debate. We investigated the effect of Toxocara canis (T. canis) infection on airway function in BALB/c mice at various days post-infection. Within 24 h after infection, the trachea responded hyperreactive to carbachol stimulation. Eosinophils, and to a lesser degree lymphocytes, infiltrated the airways causing interstitial and alveolar inflammation (7 d post-infection). Concurrently with cell infiltration, the trachea became hyporesponsive to carbachol whereas the pulmonary resistance was increased and the dynamic compliance decreased. The hyporeactive response could be simulated in vitro by incubating normal tracheae with eosinophil-enriched bronchoalveolar lavage cells obtained from infected mice. The response depended on the number of cells added to the medium, a lower number causing a hyper- and a higher number a hyporeactive response. Anti-interleukin-5 (anti-IL-5) producing hybridoma cells given simultaneously with T. canis infection inhibited eosinophil infiltration in the airways but not that of lymphocytes. Anti-IL-5 treatment prevented tracheal hyporeactivity but not perivascular and peribronchial edema, increased pulmonary resistance, or decreased dynamic compliance. Treatment with isotype control antibody did not affect eosinophil number nor the observed changes in airway functions. It was concluded that T. canis-induced airway inflammation coincided with increased pulmonary resistance, decreased dynamic compliance, and perivascular/peribronchial edema. These phenomena were independent on the presence of eosinophils, whereas tracheal hyporeactivity was clearly associated with airway eosinophilia.
Buijs
J
J
Department of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, The Netherlands.
Egbers
M W
MW
Lokhorst
W H
WH
Savelkoul
H F
HF
Nijkamp
F P
FP
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D002217:Carbachol / Q000494:pharmacology; D004802:Eosinophilia / Q000276:immunology / Q000503:physiopathology*; D004804:Eosinophils / Q000276:immunology; D006825:Hybridomas / Q000276:immunology; D066298:In Vitro Techniques; D015848:Interleukin-5 / Q000276:immunology* / Q000502:physiology; D008170:Lung Compliance / Q000502:physiology; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011657:Pulmonary Eosinophilia / Q000276:immunology / Q000503:physiopathology; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000502:physiology; D017166:Toxocara canis; D014120:Toxocariasis / Q000276:immunology / Q000503:physiopathology*; D014132:Trachea / Q000503:physiopathology*
D000911:Antibodies, Monoclonal; D015848:Interleukin-5; D011950:Receptors, Cholinergic; D002217:Carbachol